2-PAM Autoinjectors Sources Sought Notice

The Office of the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) intends to use responses to this Sources Sought Notice (SSN) for planning potential future acquisitions. BARDA seeks pertinent marketplace data on availabilities and capabilities for procuring, stockpiling, and investing in the late-stage development of Pralidoxime (2-pyridine aldoxime methyl chloride; 2-PAM) autoinjectors for intramuscular injection. BARDA seeks information on availability, capabilities, and other pertinent marketplace data to support late-stage activities required for Food and Drug Administration (FDA) approval of 2-PAM (600 mg) autoinjectors. This information is intended to strengthen BARDA’s understanding of the current and future marketplace and enhance its ability to obtain quality services economically and efficiently, and to lawfully establish potential vendor source files and listings. BARDA will not award any contracts under this Notice.